Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05789303 | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | PHASE2 | RECRUITING | 83 | — | — | May 30, 2023 | Jul 1, 2028 | Dec 22, 2025 | 1 | United States |
No prior CAR T-cell therapy cohort: Rate of very good partial response (VGPR) or better after 6 cycles according to the 2016 International Myeloma Working Group (IMWG) Response Criteria by Independent Review Committee (IRC).
Prior CAR T-cell therapy cohort: Rate of overall response (ORR) as determined by investigator assessment.
| Arm | Type | Description |
|---|---|---|
| Cohort 1: No Prior CAR T-Cell Therapy | EXPERIMENTAL | This cohort will consist of 19 participants who have not had CAR T-Cell Therapy. Participants will receive belantamab mafodotin, carfilzomib, pomalidomide and dexamethasone. |
| Cohort 2: Prior CAR T-Cell Therapy | EXPERIMENTAL | This cohort will consist of 64 participants who have had prior CAR T-Cell Therapy. Participants will receive belantamab mafodotin, carfilzomib, pomalidomide and dexamethasone. |
| Name | Type | Description |
|---|---|---|
| Belantamab mafodotin | DRUG | Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles) |
| Carfilzomib | DRUG | Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15 Cycles 2-8: 56 mg/m2 on Days 1/8/15 Cycles 9+: 56 mg/m2 on Days 1/15 |
| Pomalidomide | DRUG | 3 mg Day 1-21 of 28-day Cycle |
| Dexamethasone | DRUG | Cycles 1-4: 40 mg Days 1/8/15/22 Cycles 5+: 20 mg Days 1/8/15/22 |
1. Subject must be ≥ 18 years of age. 2. Life expectancy of more than three months. 3. Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 4. Subject must have adequate organ function, defined by clinically confirmed lab values set by the study team. 5. Female Su...